MGMT promoter hypermethylation is a validated biomarker for the efficacy of TMZ in glioblastoma [13], and is under active investigation in gastrointestinal malignancies, including colorectal cancers [14, 15, 16] and biliary tract cancers [17]. Here, MGMT is linked to glioblastoma.